EMD-46597

Single-particle
3.1 Å
EMD-46597
3D View Gallery
Deposition: 15/08/2024
Map released: 23/07/2025
Last modified: 30/07/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-46597

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9d6l summary report (pdf.gz) Map-9d6l FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Human Sec61 complex inhibited by KZR-261

EMD-46597

Single-particle
3.1 Å
EMD-46597
3D View Gallery
Deposition: 15/08/2024
Map released: 23/07/2025
Last modified: 30/07/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: Human-yeast chimeric Sec complex
Fitted models: 9d6l

Deposition Authors: Park E , Wang L
Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity.
Lowe E, Anderl JL , Bade D, Delgado-Martin C, Dong C, Fan RA, Fang Y, Jiang J, Johnson HWB, Kempema A, McGilvray P, McMinn D, Millare B, Muchamuel T, Poweleit N, Qian Y, Rehan S, Scapin G, Sugahara A, Tranter D, Tuch B, Wang J, Wang L, Whang JA, Zuno-Mitchell P, Paavilainen VO, Park E , Taunton J, Kirk CJ, Anand NK
(2025) J Pharmacol Exp Ther , 392 , 103634 - 103634
PUBMED: 40669140
DOI: doi:10.1016/j.jpet.2025.103634
ISSN: 1521-0103
Grant Support: